We are approaching the 2013-2014 respiratory syncytial virus (RSV) season, which is November through March in the United States. RSV is the most common cause of bronchiolitis and pneumonia among children younger than one year of age. During the RSV season, we will approve the monthly administration of Synagis^® (palivizumab) for at-risk children younger than two years of age. It is mandatory for all participating providers to obtain Synagis^® (palivizumab) through ACRO Pharmaceutical Services, an independent company. IBC will coordinate with ACRO Pharmaceutical Services to facilitate delivery of Synagis^® (palivizumab) to your office. If you have questions about the Synagis^® (palivizumab) distribution program, please contact Customer Service at 1-800-ASK-BLUE. Look for more information regarding the shipment and facilitation of Synagis^® (palivizumab) in the October edition of Partners in Health Update^SM. Note: MedImmune, LLC, the makers of Synagis^® (palivizumab), has a voluntary program called RSV Connection^TM; however, IBC does not participate in this program.

This is not a statement of benefits. Benefits may vary according to state requirements, product line (HMO, PPO, etc.), and/or employer groups. Member coverage can be verified by calling Customer Service at 1-800-ASK-BLUE.